Article info

Download PDFPDF
Extended report
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial

Authors

  • Edward M Vital NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK PubMed articlesGoogle scholar articles
  • Shouvik Dass NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK PubMed articlesGoogle scholar articles
  • Maya H Buch NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK PubMed articlesGoogle scholar articles
  • Andrew C Rawstron Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK PubMed articlesGoogle scholar articles
  • Paul Emery NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Paul Emery, Chapel Allerton Hospital, Leeds LS7 4SA, UK; p.emery{at}leeds.ac.uk
View Full Text

Citation

Vital EM, Dass S, Buch MH, et al
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial

Publication history

  • Received August 30, 2013
  • Revised December 14, 2013
  • Accepted December 27, 2013
  • First published January 17, 2014.
Online issue publication 
November 02, 2019

Article Versions